No Debt / Low Financial LeverageHaving no recorded total debt materially reduces fixed financing obligations and bankruptcy risk, giving management structural flexibility to prioritize R&D and clinical programs. Over 2–6 months this lowers near-term solvency pressure versus peers with leverage.

Differentiated Scientific Focus (α10β1)A focused proprietary target (α10β1) creates a durable scientific differentiation and potential competitive moat in both orthopedic cell therapy and certain cancer applications. If clinical progress continues, this specialization supports long-term licensing, partnerships, or product franchises.

Relative Gross Profit Strength / Improving FCF TrendStrong gross margins on the limited revenues seen suggest underlying unit economics could scale. Coupled with reported free cash flow improvement versus 2024, this indicates potential for margin recovery as revenues grow and fixed R&D/G&A are controlled over coming months.

Bears Say

Heavy Cash BurnSustained ~-37M TTM cash outflows materially erode runway and force repeated external financing or program cuts. For an early biotech, persistent negative OCF/FCF within 2–6 months increases dilution risk and constrains the ability to advance multiple clinical programs concurrently.

Negative Shareholders' EquityMeaningfully negative equity reflects accumulated losses and shrinking asset base, weakening balance sheet credibility. Over months this limits financing alternatives, may increase cost of capital, and constrains strategic flexibility for partnerships or acquisitions.

Small, Declining Revenue BaseA small and volatile revenue base reduces ability to cover fixed costs and demonstrates commercialization challenges. Persistent revenue decline over the TTM period undermines self-funding prospects and increases reliance on external capital in the medium term.

Xintela AB News

1XT Upcoming Earnings Report: What to Expect?

Xintela AB (1XT) is scheduled to report 2nd quarter earnings on 08/29/2025. Regarding Q2 estimates, Wall Street analysts...

6M ago

1XT Upcoming Earnings Report: What to Expect?

Xintela AB (1XT) is scheduled to report 1st quarter earnings on 05/24/2024. Regarding Q1 estimates, Wall Street analysts...

2y ago

1XT

XINT FAQ

What was Xintela AB’s price range in the past 12 months?

Xintela AB lowest stock price was kr0.24 and its highest was kr0.70 in the past 12 months.

What is Xintela AB’s market cap?

Xintela AB’s market cap is kr240.29M.

When is Xintela AB’s upcoming earnings report date?

Xintela AB’s upcoming earnings report date is Feb 27, 2026 which is in 9 days.

How were Xintela AB’s earnings last quarter?

Xintela AB released its earnings results on Nov 04, 2025. The company reported -kr0.01 earnings per share for the quarter, beating the consensus estimate of -kr0.02 by kr0.01.

Is Xintela AB overvalued?

According to Wall Street analysts Xintela AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xintela AB pay dividends?

Xintela AB does not currently pay dividends.

What is Xintela AB’s EPS estimate?

Xintela AB’s EPS estimate is -0.01.

How many shares outstanding does Xintela AB have?

Xintela AB has 861,266,850 shares outstanding.

What happened to Xintela AB’s price movement after its last earnings report?

Xintela AB reported an EPS of -kr0.01 in its last earnings report, beating expectations of -kr0.02. Following the earnings report the stock price went down -6.236%.

Which hedge fund is a major shareholder of Xintela AB?

Currently, no hedge funds are holding shares in SE:XINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Xintela AB

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.